📊 CELZ Key Takeaways
Investment Thesis
CELZ is a pre-revenue or near-zero revenue biotech company with severe operational losses and negative cash burn, losing $5.9M in operating cash flow against only $6K in annual revenue. Despite maintaining adequate liquidity ($7.2M cash), the company is burning capital at an unsustainable rate with no demonstrated path to profitability or revenue generation. The biological products company shows no evidence of commercial traction or viable product portfolio.
CELZ Strengths
- Strong liquidity position with $7.2M cash and 25.97x current ratio provides near-term runway
- Reasonable debt/equity ratio of 0.68x limits financial leverage risk
- Gross margin of 63.4% on limited revenue suggests potential unit economics if scaled
CELZ Risks
- Catastrophic revenue collapse of 45.5% YoY to only $6K indicates complete loss of commercial viability
- Operating cash burn of $5.9M annually against minimal revenue is unsustainable; at current burn rate, cash exhaustion within 14 months
- Massive operating losses of $6.1M (-102,380% margin) with no clear path to profitability or commercialization
- Zero insider purchases in last 90 days signals lack of management confidence
- Biological products company with no revenue suggests failed product pipeline or market rejection
Key Metrics to Watch
- Quarterly revenue trend and any new product commercialization announcements
- Monthly cash burn rate and projected runway until capital depletion
- Operating cash flow trajectory and achievement of cash flow positive operations
- Any clinical trial progress, regulatory approvals, or partnership announcements for revenue-generating products
CELZ Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 25.97x current ratio provides a solid financial cushion.
CELZ Profitability Ratios
CELZ vs Healthcare Sector
How CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CELZ Balance Sheet & Liquidity
CELZ 5-Year Financial Trend
5-Year Trend Summary: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s revenue has declined by 93% over the 5-year period, indicating business contraction. The most recent EPS of $-3.71 indicates the company is currently unprofitable.
CELZ Growth Metrics (YoY)
CELZ Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.0M | $-0.48 |
| Q2 2025 | N/A | -$1.2M | $-0.48 |
| Q1 2025 | N/A | -$1.0M | $0.73 |
| Q3 2024 | N/A | -$1.0M | N/A |
| Q2 2024 | N/A | -$1.1M | N/A |
| Q1 2024 | N/A | -$1.0M | N/A |
| Q3 2023 | $6.0K | -$982.3K | N/A |
| Q2 2023 | N/A | -$1.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CELZ Capital Allocation
CELZ SEC Filings
Access official SEC EDGAR filings for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CIK: 0001187953)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CELZ
What is the AI rating for CELZ?
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CELZ's key strengths?
Strong liquidity position with $7.2M cash and 25.97x current ratio provides near-term runway. Reasonable debt/equity ratio of 0.68x limits financial leverage risk.
What are the risks of investing in CELZ?
Catastrophic revenue collapse of 45.5% YoY to only $6K indicates complete loss of commercial viability. Operating cash burn of $5.9M annually against minimal revenue is unsustainable; at current burn rate, cash exhaustion within 14 months.
What is CELZ's revenue and growth?
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. reported revenue of $6.0K.
Does CELZ pay dividends?
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. does not currently pay dividends.
Where can I find CELZ SEC filings?
Official SEC filings for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CIK: 0001187953) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CELZ's EPS?
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. has a diluted EPS of $-2.52.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.